Immunocore Holdings IMCR
NASDAQ IMCR
$36.13 -1.44 (-3.85%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immunocore Holdings (IMCR) Other Non-Current Liabilities (2022 - 2026)

Immunocore Holdings (IMCR) posted Other Non-Current Liabilities of $96.6 million for Q3 2025, up 15.06% sequentially from $84.0 million in Q2 2025, and up 3113.71% YoY from $3.0 million in Q3 2024.

Analysis

Immunocore Holdings (IMCR) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends

Immunocore Holdings has reported Other Non-Current Liabilities for 7 years, with the latest figure at $96.6 million in Q3 2025.

  • Quarterly Other Non-Current Liabilities rose 3113.71% year-over-year to $96.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $96.6 million (up 3113.71% YoY) and the FY2023 annual result came in at $978000.0, down 55.85% from the prior year.
  • Other Non-Current Liabilities grew to $96.6 million in Q3 2025 per IMCR's latest filing, from $84.0 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $96.6 million in Q3 2025 and troughed at $76836.6 in Q4 2021.
  • A 5-year average of $22.9 million and a median of $2.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
  • The sharpest annual moves came in 2021 and 2025: Other Non-Current Liabilities tumbled 57.83% in 2021, then surged 3919.15% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $76836.6 in 2021, then soared by 74.02% to $133713.8 in 2022, then surged by 631.41% to $978000.0 in 2023, then surged by 207.36% to $3.0 million in 2024, then soared by 3113.71% to $96.6 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $96.6 million, $84.0 million, and $62.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Immunocore Holdings 1.85 Bn 965.54 Mn 114.84 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 26.88 Mn
Sep 30, 2025 96.60 Mn
Jun 30, 2025 83.96 Mn
Mar 31, 2025 62.48 Mn
Sep 30, 2024 3.01 Mn
Jun 30, 2024 2.09 Mn
Mar 31, 2024 2.16 Mn
Dec 31, 2023 978,000.00
Dec 31, 2022 2.22 Mn